Keywords: fda, accepts, gsk, coreg, cr, nda, review
FDA accepts GSK's Coreg CR NDA for review
Article | 20 March 2006
UK drug major GlaxoSmithKline says that the New Drug Application for its beta-blocker Coreg CR (carvedilol phosphate controlled-release capsules), which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
